<script lang="ts">
    // This component displays the Sarepta case study content
</script>

<div class="sarepta-case-study">
    <div class="container mx-auto p-8 max-w-4xl">
        <h1 class="text-3xl font-bold text-slate-800 mb-8">Sarepta Therapeutics: PRV Case Study</h1>
        
        <div class="prose prose-slate max-w-none">
            <h2 class="text-2xl font-semibold text-slate-700 mb-4">Executive Summary</h2>
            <p class="text-slate-600 mb-6">
                Sarepta Therapeutics provides a compelling example of how Priority Review Vouchers (PRVs) can shape a company's pipeline and financial trajectory. As a biotech firm specializing in genetic medicines for rare neuromuscular diseases, particularly Duchenne Muscular Dystrophy (DMD), Sarepta has strategically leveraged the PRV program to fund continued research and development.
            </p>

            <h2 class="text-2xl font-semibold text-slate-700 mb-4">Key Highlights</h2>
            <div class="bg-blue-50 border-l-4 border-blue-400 p-6 mb-6">
                <ul class="space-y-2 text-slate-700">
                    <li>• <strong>Four PRVs earned:</strong> The most for any single company (2016, 2019, 2021, 2023)</li>
                    <li>• <strong>Strategic monetization:</strong> Sold vouchers to fund R&D pipeline development</li>
                    <li>• <strong>$102M voucher sale:</strong> Used proceeds to support 40+ development programs</li>
                    <li>• <strong>Premium pricing:</strong> Elevidys priced at $3.2M per dose</li>
                </ul>
            </div>

            <h2 class="text-2xl font-semibold text-slate-700 mb-4">Business Impact</h2>
            <p class="text-slate-600 mb-4">
                The availability of PRVs has reinforced Sarepta's focus on rare pediatric indications. Each successful therapy targeting different DMD mutations provided not only therapeutic value but also the potential for additional vouchers, creating a compelling business case for continued investment in rare disease research.
            </p>

            <h2 class="text-2xl font-semibold text-slate-700 mb-4">Market Implications</h2>
            <p class="text-slate-600 mb-4">
                Sarepta's success demonstrates both the promise and challenges of the PRV program. While providing crucial funding for rare disease research, the high pricing of resulting therapies raises important questions about patient access and affordability.
            </p>

            <div class="bg-amber-50 border-l-4 border-amber-400 p-6 mt-8">
                <p class="text-sm text-amber-800">
                    <strong>Note:</strong> This case study is based on public filings and industry reports. For detailed analysis and references, please refer to the complete research documentation.
                </p>
            </div>
        </div>
    </div>
</div>

<style>
    .sarepta-case-study {
        min-height: 600px;
        background: white;
    }
    
    .prose h2 {
        border-bottom: 2px solid #e2e8f0;
        padding-bottom: 0.5rem;
    }
</style> 